Ori Biotech Secures $120M, 10-Year Partnership for Automated Cell Therapy Manufacturing; Vyriad’s In Vivo CAR-T Clears IND

September 20, 2026

RegMedNet UK

Overview

Ori Biotech announced a 10-year, $120 million partnership with an undisclosed biopharma firm to automate cell therapy manufacturing using its IRO platform, aiming to improve patient access. Concurrently, Vyriad secured IND approval for its in vivo CAR-T therapy, VV169, for multiple myeloma, initiating a Phase 1 trial. These advancements highlight a growing industry focus on manufacturing automation and novel in vivo gene-editing approaches.

In Depth

Key Findings

Ori Biotech has entered into a significant 10-year, $120 million strategic partnership with an undisclosed biopharmaceutical company to advance automated manufacturing for commercial cell therapies. This collaboration is set to drastically improve the scalability and accessibility of cell therapeutic products.

Technical / Clinical Details

The partnership centers on integrating Ori’s IRO platform, a closed, GMP-compliant automated system for cell therapy manufacturing, into the partner’s autologous cell therapy production infrastructure. The IRO platform is designed to minimize batch-to-batch variability, enhance throughput, and reduce the cost of goods sold (COGS), which are critical bottlenecks in the commercialization of cell therapies. Separately, Vyriad has received U.S. FDA Investigational New Drug (IND) approval for VV169, its in vivo CAR-T cell therapy targeting multiple myeloma, paving the way for a Phase 1 clinical trial. Additionally, Cellares and GenomeFrontier Therapeutics have initiated a collaboration to automate CAR-T manufacturing, further emphasizing the industry’s drive towards efficient, scalable production.

Background & Context

The autologous cell therapy sector has long grappled with the challenges of high manufacturing costs, complex manual processes, and limited scalability, which collectively hinder broad patient access. Ori Biotech’s substantial partnership, following its IRO platform receiving FDA’s Advanced Manufacturing Technology designation in June 2025, underscores the imperative for automated solutions. The emergence of in vivo CAR-T therapies, like Vyriad’s VV169, represents a paradigm shift from ex vivo manufacturing, potentially reducing the logistical and patient burden associated with current CAR-T treatments and expanding the reach of these life-saving therapies.

Strategic Significance & Outlook

Ori Biotech’s long-term partnership signifies a major step towards the industrialization of cell therapy manufacturing, promising to enhance cost-efficiency, consistency, and ultimately, patient access on a global scale. Vyriad’s entry into clinical development with an in vivo CAR-T therapy is a critical milestone that will test the feasibility and safety of delivering gene-editing directly within the body, potentially revolutionizing the treatment landscape for hematological malignancies. These parallel developments highlight a robust and accelerating innovation cycle across manufacturing, technological platforms, and therapeutic modalities within the regenerative medicine field.

Source: https://www.regmednet.com/cell-therapy-weekly-us120-million-10-year-cell-therapy-manufacturing-partnership/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.